GlobeNewswire: ONXEO Contains the last 10 of 11 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:53:08ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/10/26/1154545/0/en/Onxeo-Provides-Strategy-Update-and-Reports-2017-Third-Quarter-Financial-Information.html?f=22&fvtc=4&fvtv=32984Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information 2017-10-26T18:00:00Z<![CDATA[PARIS, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO)(FR0010095596), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in particular to treat orphan or resistant cancers, today provided a strategy update and announced its consolidated revenues and cash position at September 30, 2017.]]>https://www.globenewswire.com/news-release/2017/10/17/1148904/0/en/Onxeo-Reports-First-Instance-Decision-from-the-Commercial-Court-of-Paris-in-the-Lawsuit-against-SpeBio-SpePharm.html?f=22&fvtc=4&fvtv=32984Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm2017-10-17T20:01:00Z<![CDATA[PARIS, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO) (FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the Commercial Court of Paris’ decision in the litigation which started in 2009 between Onxeo on one hand and, on the other hand, SpePharm and SpeBio B.V., a joint-venture subsidiary managed by SpePharm, which was dedicated to the distribution of Loramyc®1 in Europe.]]>https://www.globenewswire.com/news-release/2017/10/02/1138455/0/en/Onxeo-Introduces-platON-a-Proprietary-Chemistry-Platform-of-Decoy-Oligonucleotides.html?f=22&fvtc=4&fvtv=32984Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides2017-10-02T05:00:00Z<![CDATA[PARIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development of innovative drugs in oncology, in particular orphan cancers, today introduced its proprietary chemistry platform of decoy oligonucleotides, platON™.]]>https://www.globenewswire.com/news-release/2017/09/28/1134139/0/en/Onxeo-announces-compelling-preclinical-data-in-combination-for-its-two-innovative-compounds-AsiDNA-and-belinostat.html?f=22&fvtc=4&fvtv=32984Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat2017-09-28T06:00:00Z<![CDATA[PARIS, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development of innovative drugs in oncology, in particular orphan cancers, today announced compelling results from extensive in-vitro preclinical studies of combinations of AsiDNA™ a first-in-class DNA break repair inhibitor (DBRi) with histone deacetylase inhibitor (HDACi), including belinostat, on various tumor cell lines. These data and potential future applications have been fully protected by a patent application filed today covering the use of AsiDNA™ in combination with any HDAC inhibitor in any treatment scheme.]]>Tumor Cell SurvivalAsiDNA™/belinostat Combinationhttps://www.globenewswire.com/news-release/2017/09/13/1120117/0/en/Onxeo-Grants-Exclusive-Worldwide-License-of-Validive-Developed-for-the-Treatment-of-Oral-Severe-Mucositis-to-Monopar-Therapeutics.html?f=22&fvtc=4&fvtv=32984Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics2017-09-13T06:00:00Z<![CDATA[PARIS, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announces the Company has granted a global exclusive license of its product Validive® (clonidine mucoadhesive buccal tablet) developed for the treatment of severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer to Monopar Therapeutics (Chicago, Illinois, USA), a biopharmaceutical company focused on developing innovative drug combinations to improve clinical outcomes in advanced cancer.]]>https://www.globenewswire.com/news-release/2017/09/11/1117648/0/en/Onxeo-Announces-Top-Line-Results-from-ReLive-Phase-III-Study-of-Livatag-in-Advanced-Hepatocellular-Carcinoma.html?f=22&fvtc=4&fvtv=32984Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma2017-09-11T18:00:00Z<![CDATA[PARIS, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced top line results from the phase III ReLive trial of Livatag® (doxorubicine Transdrug™) in adult patients with unresectable hepatocellular carcinoma (HCC), intolerant to sorafenib or having progressed after a systemic therapy including sorafenib, when compared to best standard of care. The study did not meet its primary endpoint of improving survival over the comparative group.]]>https://www.globenewswire.com/news-release/2017/07/05/1038803/0/en/Onxeo-Announces-Positive-Preclinical-Proof-of-Concept-Results-Confirming-AsiDNA-Activity-via-Systemic-Administration.html?f=22&fvtc=4&fvtv=32984Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration2017-07-05T05:30:00Z<![CDATA[Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor]]>https://www.globenewswire.com/news-release/2017/05/23/995310/0/en/Onxeo-Announces-10th-Positive-DSMB-Recommendation-to-Continue-Livatag-ReLive-Phase-III-Trial-in-HCC.html?f=22&fvtc=4&fvtv=32984Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC2017-05-23T16:00:00Z<![CDATA[PARIS, May 23, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the company has received the 10th unanimous recommendation from the Data Safety Monitoring Board (DSMB), to continue without modification the Phase III study of Livatag®, ReLive, in patients still undergoing treatment. The DSMB is an independent European board of experts that monitors the blind tolerability data from the study.]]>https://www.globenewswire.com/news-release/2017/05/10/982015/0/en/Onxeo-announces-allowance-of-U-S-patent-for-Livatag-in-hepatocellular-carcinoma.html?f=22&fvtc=4&fvtv=32984Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma2017-05-10T17:17:06Z<![CDATA[USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032 USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032]]>https://www.globenewswire.com/news-release/2017/04/24/970447/0/en/Clinigen-and-Onxeo-initiate-Managed-Access-programme-for-belinostat-in-Europe-for-patients-with-peripheral-T-cell-lymphoma-PTCL.html?f=22&fvtc=4&fvtv=32984Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)2017-04-24T17:41:37Z<![CDATA[PARIS, April 24, 2017 (GLOBE NEWSWIRE) -- Clinigen Group plc.’s (AIM:CLIN) (‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris:ONXEO) (Nasdaq Copenhagen:ONXEO) (‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).]]>